Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents
A Meta-Analysis of Randomized Trials
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Background—The benefits and harms of dual antiplatelet therapy (DAPT) continuation beyond 1 year after drug-eluting stent implantation as compared with 1-year DAPT remain controversial.
Methods and Results—We searched for randomized trials that compared longer than 1-year DAPT versus 1-year DAPT after drug-eluting stenting. A meta-analysis was performed by using standard frequentist and random-effects Bayesian approaches. Four trials comprising 17 650 participants were included. Compared with 1-year DAPT, extended DAPT did not affect all-cause mortality (odds ratio [OR], 1.11; 95% confidence interval [CI], 0.79–1.5; P=0.53) or cardiovascular mortality (OR, 1.03; 95% CI, 0.72–1.46; P=0.88). Extended DAPT was associated with a reduction in the risk of myocardial infarction (OR, 0.56; 95% CI, 0.43–0.73; P<0.001), nonsignificant reductions of stent thrombosis (OR, 0.46; 95% CI, 0.16–1.27; P=0.13), similar risk of stroke (OR, 0.91; 95% CI, 0.65–1.26; P=0.56), and an increased risk of major bleeding (OR, 1.49; 95% CI, 1.06–2.11; P=0.02). By using Bayesian meta-analysis, we found moderate evidence of a reduction of myocardial infarction (OR, 0.62; 95% credible intervals, 0.39–1.05) and weak evidence of an increase in major bleeding (OR, 1.66; 95% credible intervals, 0.89–3.09) associated with extended DAPT.
Conclusions—In this meta-analysis, extended DAPT beyond 1 year prevented myocardial infarctions and increased major bleedings, but the strength of evidence for these effects was not strong. DAPT continuation beyond 1 year showed no effects on mortality.
- Received May 26, 2016.
- Accepted April 7, 2017.
- © 2017 American Heart Association, Inc.